Literature DB >> 1357487

Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia.

R J Coker, R Nieman, M McBride, D M Mitchell, J R Harris, J N Weber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1357487     DOI： 10.1016/0140-6736(92)93120-c

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Patients unaware of their HIV status present to inner city accident and emergency department with respiratory complications.

Authors:  R Landau; R Coker; E Vermeulen; R Touquet; J Fothergill; M C Poznansky
Journal:  J Accid Emerg Med       Date:  1997-09

Review 2.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

Review 3.  AIDS and the lung: update 1995. 1. Pneumocystis carinii pneumonia.

Authors:  R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

4.  Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Authors:  J Falloon; J Lavelle; D Ogata-Arakaki; A Byrne; A Graziani; A Morgan; M A Amantea; K Ownby; M Polis; R T Davey
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

Authors:  G Gatti; M Merighi; J Hossein; S Travaini; R Casazza; M Karlsson; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  HIV positive patients first presenting with an AIDS defining illness: characteristics and survival.

Authors:  M C Poznansky; R Coker; C Skinner; A Hill; S Bailey; L Whitaker; A Renton; J Weber
Journal:  BMJ       Date:  1995-07-15

7.  Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.

Authors:  G Gatti; A Loy; R Casazza; F Miletich; M Cruciani; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.